Inovio Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Inovio Pharmaceuticals's estimated annual revenue is currently $6.5M per year.
- Inovio Pharmaceuticals's estimated revenue per employee is $28,472
- Inovio Pharmaceuticals's total funding is $446.4M.
- Inovio Pharmaceuticals's current valuation is $999.3M. (January 2022)
Employee Data
- Inovio Pharmaceuticals has 229 Employees.
- Inovio Pharmaceuticals grew their employee count by -22% last year.
Inovio Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | VP, Intellectual Property | Reveal Email/Phone |
4 | General Counsel | Reveal Email/Phone |
5 | VP, Engineering Operations | Reveal Email/Phone |
6 | EVP and General Counsel | Reveal Email/Phone |
7 | VP, Financial Planning & Analysis and Accounting | Reveal Email/Phone |
8 | VP Global Commercial | Reveal Email/Phone |
9 | VP, Device Quality | Reveal Email/Phone |
10 | SVP, Regulatory Affairs | Reveal Email/Phone |
Inovio Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.6M | 10 | 0% | N/A | N/A |
#2 | $4M | 26 | 13% | N/A | N/A |
#3 | $0.9M | 6 | -14% | N/A | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $10.9M | 70 | 3% | N/A | N/A |
#6 | $0.7M | 9 | 29% | N/A | N/A |
#7 | $4M | 26 | -16% | N/A | N/A |
#8 | $1.7M | 11 | 22% | N/A | N/A |
#9 | $7.6M | 49 | 2% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Inovio Pharmaceuticals?
Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery, development, and delivery of DNA vaccines with a focus on cancers and infectious diseases. The company’s SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company’s clinical programs include human papillomavirus/cervical cancer (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), and hepatitis C virus and human immunodeficiency virus vaccines. It is also advancing preclinical research and clinical development for a seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.
keywords:N/A$446.4M
Total Funding
229
Number of Employees
$6.5M
Revenue (est)
-22%
Employee Growth %
$999.3M
Valuation
N/A
Accelerator
Inovio Pharmaceuticals News
Shares of Inovio Pharmaceuticals Inc. INO, -1.77% slid 1.77% to $2.77 Wednesday, on what proved to be an all-around mixed trading session...
Shares of Inovio Pharmaceuticals Inc. INO, -4.73% slipped 4.73% to $2.82 Tuesday, on what proved to be an all-around poor trading session...
Inovio Pharmaceuticals Inc. stock outperforms market on strong trading day. Published: April 25, 2022 at 4:59 p.m. ET. By. MarketWatch Automation.
PLYMOUTH MEETING, Pa., Nov. 5, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the strategic appointments o ...
PLYMOUTH MEETING, Pa., Nov. 3, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases, and help treat cancer, and HPV-associated diseases, today announced that it has receive ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $69.2M | 233 | 4% | N/A |
#2 | $36.4M | 239 | 13% | $1.1B |
#3 | $39.2M | 297 | 0% | N/A |
#4 | $109.9M | 346 | 6% | N/A |
#5 | $137M | 406 | 12% | N/A |